New Drug Candidate May Overcome Blood Cancer Resistance
A new preclinical study shows a targeted inhibitor may help treat blood cancers that no longer respond to venetoclax.
Updated on Oct. 16, 2026 in Cancer
Live Poll
Is now a good time to prioritize funding for experimental drug research over other health initiatives?
Researchers have identified MIK665, a selective inhibitor that targets the MCL-1 protein to potentially overcome drug resistance in certain blood cancers. This preclinical discovery offers a new approach for managing hematologic malignancies that no longer respond to standard therapies like venetoclax.
Why it matters
In many blood cancers, overexpression of the MCL-1 protein creates an anti-apoptotic bypass that allows malignant cells to evade treatment. This finding explains how targeting this specific pathway could help restore cancer cell death in tumors that are otherwise refractory to existing drugs.
This preclinical study utilized murine xenograft models to evaluate MIK665, a small-molecule inhibitor designed to target the MCL-1 protein. Researchers observed that treatment triggered the activation of executioner caspases-3 and 7, though clinical efficacy has not been evaluated.
The details
MIK665 works by occupying the hydrophobic BH3-binding groove of the MCL-1 protein, effectively displacing pro-apoptotic effectors like BIM and NOXA. This displacement mobilizes BAK and BAX proteins, which form oligomers on the outer mitochondrial membrane to induce permeabilization. Consequently, the cell experiences a rapid dissipation of mitochondrial membrane potential, triggering a caspase-mediated cascade that results in programmed cell death.
Timeline
October 16, 2026: Article publication date.
Health Landscape
The development of MIK665 follows a long-standing trend in hematology research focusing on overcoming treatment evasion pathways. It specifically addresses the hurdle of venetoclax resistance, representing a shift toward targeting multiple anti-apoptotic proteins to improve survival outcomes.
For patients with blood cancers that have developed resistance to existing therapies, this preclinical study highlights an emerging area of research into survival proteins. This remains an early-stage discovery, and patients should discuss the specific mechanisms of their current treatment plan with their oncologist.
The takeaway
MIK665 represents a promising strategy for targeting the MCL-1 protein to restore cancer cell death in resistant malignancies. Patients undergoing treatment for hematologic disorders should stay informed about advances in combination therapies and discuss any concerns regarding treatment efficacy with their doctor.
Further reading
Learn more about the latest research and standard care options in the Cancer section.
Source note: This article includes information reported by Alwasat-ye.
Live Poll
Is now a good time to prioritize funding for experimental drug research over other health initiatives?
